Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale

Cardiovascular Research

Volumn 33, Issue 1, 1997, Pages 201-208

  Kiely, David G ^a,b   Cargill, Robert I ^a   Wheeldon, Nigel M ^a   Coutie, Wendy J ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

Author keywords

angiotensin II; angiotensin receptor; human; losartan; pulmonary hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COR PULMONALE; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPOXEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING;

AGED; ALDOSTERONE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; LOSARTAN; LUNG DISEASES, OBSTRUCTIVE; MALE; PULMONARY HEART DISEASE; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VASCULAR RESISTANCE;

EID: 0031024065     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00180-0     Document Type: Article

References (49)

1. Fishman AP. Hypoxia on the pulmonary circulation:how and where it acts. Circ Res. 38:1976;221-231.
2. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive lung disease. Thorax. 43:1988;183-189.
3. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1:1981;681-685.
4. Timms RM, Fareed UK, Williams GW, Nocturnal Oxygen Therapy Trial Group. Haemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 102:1985;29-36.
5. MacNee W, Wathen CG, Flenley DC, Muir AD. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis. 137:1988;1289-1295.
6. Cargill RI, Lipworth BJ. The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Br J Clin Pharmacol. 40:1995;11-18.
7. Segel N, Harris P, Bishop JM. The effects of synthetic hypertension on the systemic and pulmonary circulations in man. Clin Sci. 20:1960;49-61.
8. Lipworth BJ, Dagg KD. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest. 105:1994;1360-1364.
9. Farber MO, Kiblawi SSO, Strawbridge RA, Robertson GL, Weinberger MH, Manfredi F. Studies on plasma vasopressin and the renin-angiotensin-aldosterone system in chronic obstructive lung disease. J Lab Clin Med. 90:1977;373-380.
10. Farber MO, Roberts LR, Weinberger MH, Robertson G, Fineberg NS, Manfredi F. Abnormalities of sodium and water handling in chronic obstructive lung disease. Intern Med. 142:1982;1326-1330.
11. Berk BC, Veckstein V, Gordon HM, Tsuda T. Angiotensin II stimulated synthesis in cultured vascular smooth muscle cells. Hypertension. 13:1989;305-314.
12. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat. Lab Invest. 33:1975;57-61.
13. Berkov S. Hypoxic pulmonary vasoconstriction in the rat. The necessary role of angiotensin II. Circ Res. 35:1974;256-261.
14. McMurtry IF. Angiotensin is not required for hypoxic constriction in salt solution-perfused rat lungs. J Appl Physiol. 56:1984;375-380.
15. Cargill RI, Lipworth BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest. 2:1996;424-429.
16. Kiely DG, Cargill RI, Lipworth BJ. Acute hypoxic pulmonary vasoconstriction in man is attenuated by type 1 angiotensin II receptor blockade. Cardiovasc Res. 30:1995;875-880.
17. Boschetti E, Tantucci C, Cocchieri M, Fornari G, Grassi V, Sorbinin CA. Acute effects of captopril in hypoxic pulmonary hypertertension. Respiration. 48:1985;296-302.
18. Takada K, Hayashi M, Takahashi K, Yasui S. Acute effects of oral captopril on haemodynamics in patients with cor pulmonale. Jpn Circ J. 50:1986;1055-1061.
19. Bertoli L, Cicero SL, Busnardo I, Rizzato G, Montanari G. Effects of captopril on haemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. Respiration. 49:1986;251-256.
20. Zielinski J, Hawrylkiewicz I, Gorecka D, Gluskowski J, Koscinska M. Captopril effects on pulmonary and systemic haemodynamics in chronic cor pulmonale. Chest. 90:1986;562-565.
21. Burke CM, Harte M, Duncan J, et al. Captopril and domiciliary oxygen in chronic airflow obstruction. Br Med J. 290:1985;1251.
22. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol. 59:1987;662-668.
23. Brown RA, Beck JS. Comparison of several groups: the analysis of variance. In: Medical Statistics on Microcomputers. London: British Medical Journal Publishing, 1990:34-42.
24. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-51.
25. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 83:1991;1333-1342.
26. Rhaleb NE, Rouissi N, Nantel F, d'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension. 17:1991;480-484.
27. Munafo A, Christen Y, Nussberger J, et al. Drug concentration-response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 51:1992;513-521.
28. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens. 4:((suppl)):1991;350S-354S.
29. Jaiswal N, Diz DI, Tallant EA, Khoshla MC, Ferrario CM. The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens. 4:1991;228-233.
30. Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW. Prevention of thromboxane A2 receptor mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther. 268:1994;747-752.
31. Leung KH, Roscoe WA, Smith RD, Timmermans PBMWM, Chiu AT. DuP 753, a non-peptide angiotensin II receptor antagonist does not have a direct stimulatory effect on prostacyclin and thromboxane synthesis. FASEB J. 5:1991;A1767.
32. Trachte GJ, Ferrario CM, Khoshla MC. Selective blockade of angiotensin responses in the rabbit isolated vas deferens by angiotensin receptor antagonists. J Pharmacol Exp Ther. 255:1990;929-934.
33. Gottlieb SS, Dickstein K, Fleck E, et al. Haemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:((part 1)):1993;1602-1609.
34. Doig JK, MacFadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt depletion in normal human volunteers. J Cardiovasc Pharmacol. 25:1995;511-517.
35. Lipworth BJ, Dagg KD. Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. Br J Clin Pharmacol. 37:1994;273-278.
36. Cargill RI, Lipworth BJ. Haemodynamic and endocrine effects of ANP and BNP in cor pulmonale. Chest (in press).
37. Matsuda M., Sekiguchi T, Sugishita Y, Kuwako K, Iida K, Ito I. Reliability of non-invasive estimates of pulmonary hypertension by pulsed Doppler echocardiography. Br Heart J. 56:1986;158-164.
38. Cargill RI, Lipworth BJ. Pulmonary vasorelaxant effects of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax. 50:1995;183-185.
39. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 78:1986;1362-1374.
40. Beard JT, Newman JH, Loyd JE, Byrd BF. Doppler estimation of changes in pulmonary artery pressure during hypoxic breathing. J Am Soc Echo. 4:1991;121-130.
41. Chow LC, Dittrich HC, Hoit BD, Moser KM, Nicod PH. Doppler assessment of changes in right-sided cardiac haemodynamics after pulmonary thromboendarterectomy. Am J Cardiol. 61:1988;1092-1097.
42. Huntsman LL, Stewart DK, Barnes SR, Franklin SB, Colocousis JS, Hessel EA. Noninvasive Doppler determination of cardiac output in man. Circulation. 67:1983;593-602.
43. Tuck ML, Dluhy RG, Wiliams GH. Sequential response of the renin-angiotensin-aldosterone axis to acute postural change: effect of dietary sodium. J Lab Clin Med. 86:1975;754-763.
44. Wiliams GH, Cain JP, Dluhy RG, et al. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion and sodium loading. J Clin Invest. 51:1972;1731-1742.
45. Bougas J, Flood C, Little B, Tait JF, Tait SAS, Underwood R. Dynamic aspects of aldosterone metabolism. In: Bailieu EE, Robel P, eds. Aldosterone, Oxford: Blackwell Scientific Publications, 1964:25-50.
46. Rosolowsky LJ, Campbell WB. Bradykinin stimulates aldosterone release from cultured bovine adrenocortical cells through bradykinin B2 receptors. Endocrinology. 130:1992;2067-2075.
47. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Circulation. 86:1992;12-21.
48. Pratt RE, Dzau VJ. Trophic effects of angiotensin on blood vessels and heart. In: Robertson IS, Nicholls MG, eds. The Renin-Angiotensin System. London: Gower Medical Publishing, 1993;31.1-31.7.
49. Pratt RE, Dzau VJ. Trophic effects of angiotensin on blood vessels and heart. In: Robertson IS, Nicholls MG, eds. The Renin-Angiotensin System. London: Gower Medical Publishing, 1993;31.1-31.7.